<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683719</url>
  </required_header>
  <id_info>
    <org_study_id>LP0133-1273</org_study_id>
    <nct_id>NCT03683719</nct_id>
  </id_info>
  <brief_title>Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema</brief_title>
  <official_title>A Phase 2b, Double-blind, Randomised, 5-arm, Vehicle-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of Twice Daily Topical Application of Delgocitinib Cream 1, 3, 8, and 20 mg/g for 16 Weeks in Adult Subjects With Mild to Severe Chronic Hand Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group
      trial. The trial is designed to establish a dose-response signal and to investigate the
      efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to
      severe chronic hand eczema.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement (IGA treatment success) from baseline to Week 16.</measure>
    <time_frame>Week 0 to Week 16.</time_frame>
    <description>IGA is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hand Eczema Severity Index (HECSI) from baseline to Week 16.</measure>
    <time_frame>Week 0 to Week 16.</time_frame>
    <description>HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to IGA treatment success.</measure>
    <time_frame>Week 0 to Week 16.</time_frame>
    <description>Time to IGA treatment success response is defined as the time from baseline to first assessment of an IGA score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Chronic Hand Eczema</condition>
  <arm_group>
    <arm_group_label>Delgocitinib cream 1 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib cream applied twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 3 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib cream applied twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 8 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib cream applied twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 20 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delgocitinib cream applied twice daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Delgocitinib cream vehicle applied twice daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib cream</intervention_name>
    <description>Cream for topical application.</description>
    <arm_group_label>Delgocitinib cream 1 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 20 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 3 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 8 mg/g</arm_group_label>
    <other_name>LEO 124249 cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib cream vehicle</intervention_name>
    <description>The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.</description>
    <arm_group_label>Delgocitinib cream vehicle</arm_group_label>
    <other_name>LEO 124249 cream vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Age 18 years or above.

          -  Diagnosis of chronic hand eczema defined as hand eczema, which has persisted for more
             than 3 months or returned twice or more within the last 12 months.

          -  Disease severity graded as mild to severe according to IGA (i.e., IGA â‰¥2).

          -  Recent history (within 1 year before the screening visit) of inadequate response to
             topical corticosteroid treatment or topical corticosteroid treatment being medically
             inadvisable.

          -  Diagnostic patch testing performed within 3 years prior to the screening visit.

        Key Exclusion Criteria:

          -  Concurrent skin diseases on the hands e.g tinnea manuum.

          -  Active atopic dermatitis in regions other than the hands or psoriasis requiring
             medical treatment.

          -  Clinically significant infection (e.g., impetiginised hand eczema) on the hands.

          -  Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, or
             corticosteroids within 4 weeks prior to baseline.

          -  Psoralen ultraviolet A (PUVA) or ultraviolet B (UVB) therapy on the hands within 4
             weeks prior to baseline.

          -  Receipt of live attenuated vaccines 4 weeks prior to baseline.

          -  Cutaneously applied treatment with immunomodulators (e.g., phosphodiesterase-4 (PDE-4)
             inhibitors, pimecrolimus, tacrolimus) or topical corticosteroids on the hands within 2
             weeks prior to baseline.

          -  Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2
             weeks prior to baseline.

          -  Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e.,
             subjects must not start antihistamine treatment or change the current dosage regime
             within 2 weeks prior to baseline.

          -  Other cutaneously applied therapy on the hands (except for the use of subject's own
             emollients) within 1 week prior to baseline.

          -  Cutaneously applied treatments in regions other than the hands, which could interfere
             with clinical trial evaluations or pose a safety concern within 1 week prior to
             baseline.

          -  Receipt of any marketed or investigational biologic agents within 6 months or 5
             half-lives prior to baseline or until cells count returns to normal, whichever is
             longer.

          -  Clinically significant infection (systemic infection or serious skin infection
             requiring parenteral treatment) within 4 weeks prior to baseline.

          -  Tuberculosis requiring treatment within 12 months prior to screening and/or subjects
             with a positive blood test for tuberculosis at screening.

          -  History of any known primary immunodeficiency disorder including a positive human
             immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral
             medications.

          -  Any disorder which is not stable and in the investigator's opinion could affect the
             safety of the subject, influence the findings of the trial, or impede the subject's
             ability to complete the trial.

          -  Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),
             hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (anti-HCV) serology
             at screening. Subjects with positive HBsAb may be randomised provided they are
             hepatitis B vaccinated and have negative HBsAg and HBcAb.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-4501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Bremerhaven</city>
        <zip>27574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>GÃ¶ttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Langenau</city>
        <zip>89129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>LÃ¼beck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Selters</city>
        <zip>56242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70499</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo Pharma Investigational Site</name>
      <address>
        <city>Wuppertal</city>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_url>https://www.leopharmatrials.com/For-professionals</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

